New FDA-approved clot removal devices show promise for treating stroke patients

February 26, 2013
New FDA-approved clot removal devices show promise for treating stroke patients
Dr. David Fiorella with patient Shelley Broven.

Specialists at Stony Brook Medicine's Cerebrovascular and Stroke Center (CVC) are treating patients with a new generation of blood clot removal devices that show promise in successfully revascularizing stroke patients, including those with large vessel blockages. The Solitaire Flow Restoration Device and the Trevo device, approved by Food and Drug Administration (FDA) in 2012 to treat stroke caused by the sudden obstruction of a brain blood vessel (acute ischemic stroke) showed improved results over a previous standard and first generation clot-removal device in clinical trials. 

"We have had excellent outcomes using these new devices," said David Fiorella, M.D., Ph.D., a Professor of Clinical Neurological Surgery and Radiology at Stony Brook University School of Medicine and Co-Director of the CVC. "In , 'time is brain,' and in some cases just minutes matter. Therefore, restoring blood flow in an effective and timely manner is critical to the survival and recovery of . These new devices enable us to quickly restore blood flow and retrieve the clot in most patients," said Dr. Fiorella, who has performed some 30 procedures on stroke patients using the new devices. 

"These blot clot removal devices are an important new component of our against stroke" said Henry Woo, MD, Professor of and Radiology and Co-Director of the CVC, who has also used both devices in patient procedures. "Our center provides endovascular treatment for 24/7, and by having the latest technologies to remove brain , and the expertise to perform endovascular procedures, our Center remains on the cutting-edge against this life-threatening condition." 

According to the American Stroke Association, stroke remains the fourth leading cause of death and leading cause of adult disability in the United States. On average a stroke occurs every 40 seconds in the country, and someone dies from a stroke every four minutes. These statistics speak to the need to develop more effective drugs, devices, and procedures to treat stroke.  

The video will load shortly

Recent results of clinical trials reported in The New England Journal of Medicine (February 2013) about the use of first generation of blood clot removal devices in the endovascular treatment of acute revealed that endovascular treatment does not result in better patient outcomes compared to standard drug treatments. Dr. Fiorella contends that while these trial results are important in the search for the best treatment protocols for acute ischemic stroke, the new devices and techniques are markedly better than those used to treat the majority of patients in these trials and may yet prove to be the most effective approach in select patients. Further research trials are being conducted at Stony Brook to investigate the efficacy of these newer, better devices in acute ischemic stroke. 

The new devices that Stony Brook cerebrovascular specialists use to perform revascularization are expandable wire-mesh systems that collapse and are delivered into the brain blood vessels through small flexible tubes (microcatheters) which are guided from the groin to the brain. The devices open at the site of the clot, displacing the occlusion and immediately restoring blood flow to the brain. When the devices are withdrawn from the blood vessel, they take the clot with them, allowing the clot to be removed from the blood vessel. 

Dr. Fiorella said that while intravenous clot-busting drugs remain a standard part of stroke therapy, endovascular therapies using the new devices are particularly beneficial when treating certain stroke patients. 

"In many of the more severe stroke cases where the main arteries of the brain are blocked, intravenous medications are predictably ineffective, failing to open the occluded artery in 70 to 90 percent of the cases. Also, many patients are not eligible for intravenous clot busting medication because of their time of presentation, existing medical conditions, recent surgery, or the medications they take, such as blood thinners," he explained. "In these cases where intravenous medications are ineffective or contraindicated, endovascular treatments using these new devices offer patients the most promise." 

"I feel extremely good and am able to do the things I did before my stroke, and that includes taking care of my grandchildren and running road races," said Michael Jezewski, 66, a retiree from Centereach, N.Y., who ran a five kilometer race just two months after his May 2012 stroke. "I believe that Dr. Fiorella's procedure did save my life and contributed greatly to my quick recovery." 

Jezewski did not have a history of stroke and collapsed while at doctor's appointment. He was rushed to Stony Brook where Dr. Fiorella performed endovascular treatment with one of the new devices within two hours of Jezewski's sudden collapse. Jezewski's symptoms started with fatigue and no feeling on the right side of his body, and then quickly progressed to paralysis and the inability to speak. Upon awaking from the clot removal procedure, the majority of his symptoms had completely resolved. 

When Shelley Broven, 66, of Setauket, N.Y., began to feel dizzy and had a hard time speaking during her husband's 70th birthday party in November 2012, friends called an ambulance from the restaurant. She was rushed to Stony Brook where Dr. Fiorella performed endovascular treatment with a new generation device. 

"I don't recall much of what happened after that incident, but within a week I was out of the hospital, beginning rehabilitation, and feeling pretty good," said Broven. "Each week I have more energy and can express myself more clearly," added Broven, whose resulted from a nearly completely blocked carotid artery which sent a blood clot into her brain blood vessels. 

About the New Devices 

In two separate multicenter clinical trials reported in The Lancet the new devices were compared to a standard first generation clot removal device called the Merci Retriever.  

In one published report, the Solitaire device opened blocked arteries in approximately 70 percent of the patients, compared to only 30 percent treated with the previous device. When other therapies were used with Solitaire, the success rate improved to 80 percent. After three months, 58 percent of the patients with the Solitaire device had a good neurological outcome in comparison to 33 percent of those treated with the standard device. In addition, the mortality rates were less than half in those treated with the newer generation device. 

Another published report compared the Trevo device with the Merci Retriever. In this trial, the new Trevo device was superior to the older device, with an 86 percent success rate in opening the blocked brain vessel. When other therapies were added, the Trevo success rate was more than 90 percent. 

Explore further: New device performs better than old for removing blood clots

Related Stories

New device performs better than old for removing blood clots

February 3, 2012
An experimental blood clot-removing device outperformed the FDA-approved MERCI; retriever device, according to late-breaking science presented at the American Stroke Association's 2012 International Stroke Conference.

New device to remove stroke-causing blood clots proves better than standard tool

August 26, 2012
Stroke is the fourth leading cause of death and a common cause of long-term disability in the United States, but doctors have very few proven treatment methods. Now a new device that mechanically removes stroke-causing clots ...

The Medical Minute: Solitaire for stroke -- It's not a game

May 22, 2012
Stroke is the fourth leading cause of death in North America -- down from third. Despite this "improvement," stroke remains the leading cause of adult disability. Ischemic strokes, caused by blood vessel blockages, are by ...

Adding endovascular therapy to tPA didn't improve recovery after stroke

February 8, 2013
Adding endovascular therapy to clot-busting therapy for stroke did not significantly improve stroke recovery at three months, according to a study presented in a special symposium at the American Stroke Association's International ...

'Clot-buster' drug may still be best stroke treatment

February 7, 2013
(HealthDay)—The standard medical care for patients having an ischemic stroke is to give powerful "clot-busting" drugs as soon as possible after the start of the stroke.

Delay in breaking up blood clots means worse stroke outcome

February 11, 2013
Every 30-minute delay in breaking up a blood clot from a stroke was associated with a 10 percent decrease in the probability of a good outcome, regardless of other factors such as stroke severity, according to late-breaking ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.